The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
After a long wait, investors at last have early evidence that Nkarta’s Car-NK cells work – with a relatively clean safety profile to boot.
Praxis, Proqr and Nordic Nanovector are awaiting important data.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
The first human data from the Car-NK project FT596 are impressive – but not impressive enough for a company worth $9bn.
The glacial development of Fate’s anti-CD19 Car-NK therapy FT596 could yield real data at last.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.